BTIG raised the firm’s price target on Natera to $100 from $90 and keeps a Buy rating on the shares. The company delivered very strong metrics across the board and now expects to achieve a breakeven quarter by Q3 or sooner, yet there still remains a flurry of upside drivers to numbers, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NTRA:
- Natera announces next phase of CareDx patent infringement litigation
- Canaccord bullish on Natera growth potential as Medicare extends coverage
- Medicare extends coverage of Natera’s signatera MRD test to ovarian cancer
- NTRA Earnings this Week: How Will it Perform?
- Natera downgraded to Outperform from Strong Buy at Raymond James
